abbv-383
abbvie
 presents abbv-383, a bcmaxcd3 bispecific. ph 1 trial at 60mg dose, saw 60% overall response rate, well tolerated. #ims2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.